Patent classifications
C07C41/34
Process for producing diisopropyl ether from high purity propylene
A process for the production of diisopropyl ether from high purity propylene without the need of a propane-propylene fractionation column has been developed. The process involves (1) reacting a high purity propylene feedstock and water to produce isopropyl alcohol in a reactor and reacting the isopropyl alcohol with propylene to produce diisopropyl ether in the presence of an acidic ion exchange resin catalyst and a C.sub.4 diluent to generate a reactor effluent stream containing at least water, isopropyl alcohol, diisopropyl ether, propylene, and acid, (2) passing the reactor effluent to an acid removal zone to produce an acid-depleted stream, (3) dividing the acid-depleted stream into two portions, (4) recycling a portion to the reactor (5) purging a portion to prevent propane build-up and (6) recovering product diisopropyl alcohol.
Reduction of greenhouse gas emission
Herein disclosed is a method of reducing greenhouse gas (GHG) emission comprising introducing one or more feed streams into a reformer to generate synthesis gas; and converting synthesis gas to dimethyl ether (DME). In some cases, the reformer is a fluidized bed dry reforming reactor. In some cases, the reformer comprises a hydrogen membrane. In some cases, the hydrogen membrane removes hydrogen contained in the synthesis gas and shifts reforming reactions toward completion.
PROCESS AND SYSTEM FOR PRODUCING DIMETHYL ETHER
The invention relates to an improved process and system for the synthesis of dimethyl ether (DME) from a feedstock comprising H.sub.2 and CO.sub.x, wherein x=1-2. The process according to the invention comprises (a) subjecting the gaseous mixture comprising synthesis gas originating from step (c) to DME synthesis by contacting it with a catalyst capable of converting synthesis gas to DME to obtain a gaseous mixture comprising DME; (b) subjecting a gaseous mixture comprising the gaseous mixture originating from step (a) to a separation-enhanced reverse water gas shift reaction; and (c) subjecting the gaseous mixture originating from step (b) to DME/synthesis gas separation to obtain DME and a gaseous mixture comprising synthesis gas, which is recycled to step (a). Herein, the feedstock is introduced in step (a) or step (b) and the molar ratio of H.sub.2 to CO.sub.x in the gaseous mixture which is subjected to step (b) is at least (x+0.8). Also a system for performing the reaction according to the invention is disclosed.
METHOD FOR PREPARING 2-IODO ARYL ETHER UNDER THE ACTION OF ALKALI METAL HYDRIDE
Disclosed in the present invention is a method for preparing 2-iodo aryl ether under the action of alkali metal hydride: adding alkali metal hydride and phenol to a solvent, then adding 1,2-diiodoarene, and reacting at 0-100? C. to obtain a 2-iodo aryl ether product. The coupling process of the present invention does not require the addition of a transition metal catalyst, and does not cause metal contamination to the product; the method of the present invention can be performed at room temperature and has high functional group compatibility, and solves the problem that existing metal-catalysed coupling to aryl ether reactions need to be performed at a relatively high temperature.
METHOD FOR PREPARING 2-IODO ARYL ETHER UNDER THE ACTION OF ALKALI METAL HYDRIDE
Disclosed in the present invention is a method for preparing 2-iodo aryl ether under the action of alkali metal hydride: adding alkali metal hydride and phenol to a solvent, then adding 1,2-diiodoarene, and reacting at 0-100? C. to obtain a 2-iodo aryl ether product. The coupling process of the present invention does not require the addition of a transition metal catalyst, and does not cause metal contamination to the product; the method of the present invention can be performed at room temperature and has high functional group compatibility, and solves the problem that existing metal-catalysed coupling to aryl ether reactions need to be performed at a relatively high temperature.
Integrated process for making propene oxide and an alkyl tert-butyl ether
An integrated process for making propene oxide and an alkyl tert-butyl ether comprises dehydrogenating a feed stream comprising iso-butane to provide a stream comprising iso-butene and hydrogen and separating this stream into a stream consisting essentially of hydrogen and a stream comprising iso-butene; reacting a part or all of the stream comprising iso-butene with an alkanol in the presence of a solid acid catalyst to provide an alkyl tert-butyl ether; reacting a part or all of the stream consisting essentially of hydrogen with oxygen, providing a stream comprising hydrogen peroxide; and reacting a part or all of the stream comprising hydrogen peroxide with propene in the presence of an epoxidation catalyst to provide propene oxide.
Integrated process for making propene oxide and an alkyl tert-butyl ether
An integrated process for making propene oxide and an alkyl tert-butyl ether comprises dehydrogenating a feed stream comprising iso-butane to provide a stream comprising iso-butene and hydrogen and separating this stream into a stream consisting essentially of hydrogen and a stream comprising iso-butene; reacting a part or all of the stream comprising iso-butene with an alkanol in the presence of a solid acid catalyst to provide an alkyl tert-butyl ether; reacting a part or all of the stream consisting essentially of hydrogen with oxygen, providing a stream comprising hydrogen peroxide; and reacting a part or all of the stream comprising hydrogen peroxide with propene in the presence of an epoxidation catalyst to provide propene oxide.
Methods of purifying crude sevoflurane
A method of purifying crude sevoflurane comprising (i) providing crude sevoflurane and an aqueous base to a first centrifugal separator, wherein the crude sevoflurane comprises sevoflurane and hexafluoroisopropanol; (ii) mixing the crude sevoflurane and the aqueous base in the first centrifugal separator; and (iii) separating the sevoflurane from the aqueous base in the first centrifugal separator, thereby purifying the crude sevoflurane.
Reduction type coenzyme Q10 powder, composition thereof, and preparation method thereof
The present invention describes a reduction type coenzyme Q10 powder, a composition thereof, and a preparation method thereof. The reduction type coenzyme Q10 powder is obtained by reacting an oxidation type coenzyme Q10 with the presence of a reducing agent, removing an organic solvent and other purities from a reaction solution after the reaction is finished to obtain an oil-soluble reduction type coenzyme Q10 liquid, and then directly performing prill formation with cold wind on an obtained reduction type coenzyme Q10 greasy substance. The obtained reduction type coenzyme Q10 powder has a lower crystallinity, and in a Cu-K[alpha] X-ray diffraction spectrum, has a strong peak at a diffraction angle 2[theta] being 18.9 DEG, and has a very strong absorption peak at a diffraction angle 2[theta] being 22.8 DEG. The reduction type coenzyme Q10 powder obtained in the present invention is in an incompletely crystallized state, has desirable stability and desirable oral bioavailability, and is suitable for use in applications such as dietary supplements, cosmetics or pharmaceuticals.
Reduction type coenzyme Q10 powder, composition thereof, and preparation method thereof
The present invention describes a reduction type coenzyme Q10 powder, a composition thereof, and a preparation method thereof. The reduction type coenzyme Q10 powder is obtained by reacting an oxidation type coenzyme Q10 with the presence of a reducing agent, removing an organic solvent and other purities from a reaction solution after the reaction is finished to obtain an oil-soluble reduction type coenzyme Q10 liquid, and then directly performing prill formation with cold wind on an obtained reduction type coenzyme Q10 greasy substance. The obtained reduction type coenzyme Q10 powder has a lower crystallinity, and in a Cu-K[alpha] X-ray diffraction spectrum, has a strong peak at a diffraction angle 2[theta] being 18.9 DEG, and has a very strong absorption peak at a diffraction angle 2[theta] being 22.8 DEG. The reduction type coenzyme Q10 powder obtained in the present invention is in an incompletely crystallized state, has desirable stability and desirable oral bioavailability, and is suitable for use in applications such as dietary supplements, cosmetics or pharmaceuticals.